title: Frequent loss of heterozygosity at 6q in pheochromocytoma.
abstract: Multiple genetic alterations have been associated with pheochromocytoma (PCC). Most PCCs are sporadic, but they also occur in inherited tumor syndromes, including von Hippel-Lindau disease. Although the etiology of most inherited PCCs is well documented, little is known about the etiology of sporadic tumors. Mutations of those genes that harbor germ-line mutations in familial cases cover only 10% to 15% of somatic mutations in sporadic PCCs. A previous cytogenetic analysis indicated frequent loss of 6q in sporadic PCCs. We therefore investigated in detail 18 PCCs using 22 microsatellite markers spanning 6q to search for the presence of allele deletions and identify specific regions likely to contain tumor suppressor genes involved in PCC. Moreover, we sought to compare PCC with capillary hemangioblastoma, another von Hippel-Lindau disease-associated tumor that we previously found to harbor frequent loss of heterozygosity (LOH) at 6q. Our study revealed a high frequency (13/18; 72%) of overall 6q LOH in PCCs. Loss of heterozygosity at 6q was observed in 6 benign (6/9; 67%) and 7 borderline (7/9; 78%) tumors. We identified 2 regions where LOH or allelic imbalance was common (ie, 6q14 [9/18; 50%] and 6q23-24 [6/18; 33%]). We further focused the search using markers specific for the ZAC1 gene region located at 6q24-25. Altogether, for all 6q23-25 markers, including the ZAC1-specific ones, LOH or allelic imbalance was observed in 50% (9/18) of the PCCs. Similar to our findings for capillary hemangioblastomas, our data for the first time suggest that one or several tumor suppressor genes located at 6q, particularly at 6q23-24, may play a role in the tumorigenesis of PCCs.
authors.affiliation: Department of Pathology, University of Helsinki and HUSLAB, Helsinki, Finland.
authors.forename: Sebsebe
authors.initials: S
authors.lastname: Lemeta
authors.forename: Kaisa
authors.initials: K
authors.lastname: Salmenkivi
authors.forename: Lea
authors.initials: L
authors.lastname: Pylkkänen
authors.forename: Markku
authors.initials: M
authors.lastname: Sainio
authors.forename: Sirkku T
authors.initials: ST
authors.lastname: Saarikoski
authors.forename: Johanna
authors.initials: J
authors.lastname: Arola
authors.forename: Päivi
authors.initials: P
authors.lastname: Heikkilä
authors.forename: Caj
authors.initials: C
authors.lastname: Haglund
authors.forename: Kirsti
authors.initials: K
authors.lastname: Husgafvel-Pursiainen
authors.forename: Tom
authors.initials: T
authors.lastname: Böhling
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D022981:Allelic Imbalance; D018797:Cell Cycle Proteins / Q000235:genetics*; D002896:Chromosomes, Human, Pair 6; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D017353:Gene Deletion; D005819:Genetic Markers; D018325:Hemangioblastoma / Q000235:genetics / Q000473:pathology; D006801:Humans; D019656:Loss of Heterozygosity; D008297:Male; D018895:Microsatellite Repeats; D008875:Middle Aged; D010673:Pheochromocytoma / Q000235:genetics* / Q000473:pathology; D014157:Transcription Factors / Q000235:genetics*; D047368:Tumor Burden; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D018797:Cell Cycle Proteins; D004273:DNA, Neoplasm; D005819:Genetic Markers; C106464:PLAGL1 protein, human; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins